 phase IA trial sequential administration recombinant DNA-produced interferons combination recombinant interferon gamma recombinant interferon alfa patients metastatic renal cell carcinoma study effects recombinant interferon gamma rIFN gamma recombinant interferon alfa rIFN alpha patients metastatic renal cell carcinoma RCC rIFN alpha days dosages cohorts patients cohort patients dose rIFN alpha subsets patients rIFN gamma gamma days third week hours administration rIFN alpha Dose-limiting toxicity DLT constitutional symptoms leukopenia nephrotic syndrome acute renal failure hypotension death congestive heart failure DLT rIFN alpha gamma dose level Maximum-tolerated dose MTD rIFN alpha rIFN gamma patients minimum days therapy due toxicity rapid progression disease Clinical responses assessable patients patients complete remission complete remission months additional patients partial responses months patient partial remission slow regression pulmonary liver lesions therapy rIFNs Clinical responses durable patients complete remissions patients partial remissions results study toxicities combination rIFN therapy agents